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Abstract
Background: Individual patient meta-analysis to determine the analgesic efficacy and adverse
effects of single-dose rofecoxib in acute postoperative pain.
Methods: Individual patient information was available from 14 trials; 13 in dental and one in
postsurgical pain. For each patient the percentage of maximum possible pain relief (%maxTOTPAR)
was determined at different time points. The proportion of patients with at least 50%
maxTOTPAR, and number-needed-to-treat (NNT) for at least 50% maxTOTPAR, were then
calculated, with time when 50% of patients had remedicated (TTR50) and number-needed-to-harm
(NNH) for adverse effects.
Results: In dental pain, for rofecoxib 50 mg (1330 patients) compared with placebo (570 patients)
the NNT was 1.9 (95% confidence interval 1.8 to 2.1) for six hours, 2.0 (1.8 to 2.1) at eight, 2.4
(2.2 to 2.6) at 12, and 2.8 (2.5 to 3.1) at 24 hours. The TTR50 was 15.5 hours. Adverse effects were
uncommon, though post-extraction alveolitis (dry socket) occurred more often with rofecoxib 50
mg than with placebo, NNH 24 (14 to 80). For postsurgical pain in one trial (163 patients), the NNT
for rofecoxib 50 mg for six hours was 3.9 (2.6 to 7.8), the TTR50 was 5.8 hours, and multiple-dose
adverse effects over five days occurred at similar rates with rofecoxib 50 mg and placebo.
Conclusions: Single-dose rofecoxib 50 mg is an effective treatment with long-lasting analgesia and
few adverse effects in dental pain. More information is required to confirm efficacy in postsurgical
pain.
Background
Cox-2 selective inhibitors (coxibs), like rofecoxib, have
been developed to provide better gastrointestinal tolera-
bility than conventional non-steroidal anti-inflammatory
drugs (NSAIDs). Relatively low rates of gastrointestinal
adverse effects allow the use of higher doses of coxibs in
the acute pain setting. These high doses may have the
additional advantage of longer duration analgesia with
extended dosing intervals.
Conventionally, trials in acute pain have been conducted
over 4–6 hours because that was how long analgesia
lasted for most drugs. Validated methods exist to allow
the conversion of mean pain intensity or pain relief out-
comes into dichotomous form (the proportion of patients
Published: 11 February 2004
BMC Anesthesiology 2004, 4:3
Received: 10 November 2003
Accepted: 11 February 2004
This article is available from: http://www.biomedcentral.com/1471-2253/4/3
© 2004 Edwards et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.BMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/3
Page 2 of 10
(page number not for citation purposes)
with at least 50% pain relief) over 4–6 hours [1-4], but
methods have not yet been developed to do this beyond
six hours. For rofecoxib, a meta-analysis of mean pain out-
come data from published trials in postoperative (dental
or postsurgical) pain showed a good analgesic response
with rofecoxib 50 mg over six hours, and relatively long
duration of action (defined in the analysis by time to
remedication) [5].
When information is available from individual patients in
a trial we do not have to rely on mean values. Since actual
pain measurements are available at all time points for
each patient, it is possible to calculate for each patient the
percent of maximum pain relief (%maxTOTPAR), the
number of patients with at least 50% maxTOTPAR and,
hence, the number-needed-to-treat (NNT) for at least
50% pain relief at different durations.
The previous analysis [5] was limited to information from
five published trials and outcomes over six hours. The
objectives of this individual patient meta-analysis were to
extend the previous analysis to include more trials and
patients, and to calculate NNTs for different durations up
to 24 hours.
Methods
QUOROM guidelines for reporting meta-analyses were
followed where appropriate [6]. Merck Research Labora-
tories, Rahway, New Jersey, provided individual patient
data from 14 Phase III trials of rofecoxib in postoperative
(dental or postsurgical) pain. All completed (July 2002)
Phase III trials of rofecoxib meeting pre-specified criteria
for inclusion in the meta-analysis were provided. This
included information from five published trials in post-
operative pain in a previous review [5], but excluded
information from one Phase II study [7] which used a dif-
ferent formulation of rofecoxib. The Phase II trial had
been included in a previous meta-analysis using pub-
lished mean data [5].
Trials
The trials were randomised and double blind, and com-
pared single, oral doses of rofecoxib with an active control
and placebo in adults with moderate to severe postopera-
tive pain. Dental studies were conducted over 24 hours.
One postsurgical study was a multiple dose trial for which
information for the first dose was available over 12 hours.
In all trials, pain intensity and pain relief were measured
using a standard four-point categorical pain intensity scale
(0 none, 1 mild, 2 moderate, 3 severe) and a five-point
point pain relief scale (0 none, 1 a little, 2 some, 3 a lot, 4
complete). Pain measurements were collected using
patient diaries. Patients were assessed at baseline, then at
least hourly for eight hours, and again at 12 and 24 hours.
In some studies additional assessments were conducted
between eight, 12 and 24 hours. The exact time at which a
patient requested remedication (rescue analgesic), if
required, was recorded. Adverse effects were recorded as
the number of patients with any adverse effect(s), or of
particular adverse effects. Table 1 shows the study treat-
ments, dosing and number of patients for the individual
trials.
The quality of trials, in terms of their descriptions of ran-
domisation, double blinding and withdrawals or drop-
outs, was determined using a five point scale [8]. Study
validity was determined using a 16-point pain validity
scale [9]. These scales are described in Additional file 1.
Meta-analysis
Outcome data were pooled in an intention to treat
(number of patients randomised) analysis. For each
patient we calculated the area under the pain relief – time
curve (TOTPAR) for six, eight, 12 and 24 hours. When a
patient remedicated the pain relief score was set to zero for
all remaining time points until the end of the observation
period. For each patient we then calculated the percentage
of the maximum possible TOTPAR for each time point
(number of hours of observation multiplied by the maxi-
mum possible pain relief of 4; for example,24 for six
hours, 32 for eight hours).
When making comparisons, each active analgesic was
compared with placebo from those trials in which the
active analgesic was used. Efficacy was defined as the
number-needed-to-treat (NNT) for at least 50% pain
relief. Duration of analgesia was defined as the time when
50% of patients with the same treatment had remedicated
(TTR50).
Analyses for comparator treatments were based on infor-
mation available only from the trials of rofecoxib men-
tioned in this report, but for most there was insufficient
information to be confident of the result [10]. In acute
pain studies we need information from at least 500
patients to be sure of an NNT ± 0.5 when the NNT is 2,
and many more patients when the NNT is higher. Only
ibuprofen 400 mg had sufficient information (601
patients in six trials). While data are provided for other
comparators, only information from rofecoxib 50 mg and
ibuprofen 400 mg will be discussed. The single postsurgi-
cal study was not pooled with dental trials for observa-
tions beyond six hours because the only outcome for
which we know that these two pain models give the same
result is NNT for at least 50% maxTOTPAR for 4–6 hours
[11].
Relative benefit (or risk) was calculated using a fixed
effects model [12], with no statistically significant differ-
ence between treatments assumed when the 95%BMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/3
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confidence intervals included unity. Number-needed-to-
treat (or harm) was calculated using the method of Cook
and Sackett [13] using the pooled number of observa-
tions. NNT/H is the reciprocal of the absolute risk reduc-
tion or increase; for instance, if 75 out of 100 patients
benefit with treatment and only 25 out of 100 benefit
with placebo, the absolute risk increase is 0.75-0.25 = 0.5,
and the NNT is 1/0.5 = 2.
The following terms were used to describe adverse out-
comes in terms of harm or prevention of harm:
• When significantly fewer adverse effects occurred with
active treatment than with placebo we used the term the
number-needed-to-treat to prevent one event (NNTp).
• When significantly more adverse effects occurred with
active treatment compared with placebo we used the term
the number-needed-to-harm to cause one event (NNH).
Clinical homogeneity of trials was examined graphically
[14] since heterogeneity tests and funnel plots have been
shown to be unreliable [15,16]. The z test [17] was used
to detect statistically significant differences between the
NNTs derived for different treatments. Statistical signifi-
cance was indicated by p < 0.01.
Results
All 14 trials scored the maximum of five points for quality
and the maximum of 16 points for validity. In all 14 trials
(2060 patients) the NNT for at least 50% pain relief over
six hours was 2.0 (1.9 to 2.1) for rofecoxib 50 mg com-
pared with placebo in dental plus postsurgical pain.
Dental pain
There were 13 trials in dental pain (studies 27, 51, 66, 71,
84, 95, 104, 111, 127, 128, 152, 154, 169). Patients
underwent surgical removal of impacted third molars.
Their mean age was 21 years, and 60% were women. Sixty-
five percent of patients had moderate and 35% severe
pain at baseline. Study treatments were rofecoxib 50 mg
(1330 patients), placebo (570 patients), and active com-
parators of ibuprofen 400 mg in six trials (303 patients),
enteric-coated diclofenac sodium 50 mg in one (121
patients), naproxen sodium 550 mg in two (88 patients),
paracetamol 600 mg plus codeine 60 mg in two (360
Table 1: Trials details
Trial ID Pain 
condition
Study drug and dose, number of 
patients
Design Observations after 
8 hrs
Quality, Validity 
scores
27 Dental Rofecoxib 50 mg, 38 Naproxen 550 mg, 39 
Placebo, 39
Single oral dose, parallel 12, 24 Q 5 V 16
51 Dental Rofecoxib 50 mg, 72 Naproxen 550 mg, 49 
Placebo, 48
Single oral dose, parallel 12, 24 Q 5 V 16
66 Dental Rofecoxib 50 mg, 50 Ibuprofen 400 mg, 51 
Placebo, 50
Single oral dose, parallel 12, 24 Q 5 V 16
71 Dental Rofecoxib 50 mg, 50 Ibuprofen 400 mg, 52 
Placebo, 50
Single oral dose, parallel 12, 24 Q 5 V 16
84 Dental Rofecoxib 50 mg, 56 Ibuprofen 400 mg, 56 
Placebo, 56
Single oral dose, parallel 12, 24 Q 5 V 16
95 Dental Rofecoxib 50 mg, 90 Ibuprofen 400 mg, 46 
Placebo, 45
Single oral dose, parallel 10, 12, 24 Q 5 V 16
104 Dental Rofecoxib 50 mg, 151 Ibuprofen 400 mg, 46 
Placebo, 45
Single oral dose, parallel 10, 12, 24 Q 5 V 16
111 Dental Rofecoxib 50 mg, 159 Ibuprofen 400 mg, 53 
Placebo, 52
Single oral dose, parallel 10, 12, 24 Q 5 V 16
127 Dental Rofecoxib 50 mg, 180 Paracetamol 600 mg 
+ Codeine 60 mg, 180 Placebo, 30
Single oral dose, parallel 12, 24 Q 5 V 16
128 Dental Rofecoxib 50 mg, 182 Paracetamol 600 mg 
+ Codeine 60 mg, 180 Placebo, 31
Single oral dose, parallel 12, 24 Q 5 V 16
152 Dental Rofecoxib 50 mg, 90 Oxycodone 5 mg + 
Paracetamol 325 mg, 91 Placebo, 31
Single oral dose, parallel 12, 24 Q 5 V 16
154 Dental Rofecoxib 50 mg, 91 Oxycodone 5 mg + 
Paracetamol 325 mg, 89 Placebo, 30
Single oral dose, parallel 12, 24 Q 5 V 16
169 Dental Rofecoxib 50 mg, 121 Diclofenac 50 mg Q8 
hr, 121 Placebo, 63
Single oral dose, parallel 10, 11, 12, 16, 20, 24 Q 5 V 16
72 Postsurgical Rofecoxib 50 mg, 110 Naproxen 550 mg, 
55 Placebo, 53
Multiple with single dose 
efficacy data, AE 5 days, 
parallel
12 hrs Q 5 V 16BMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/3
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patients), and oxycodone 5 mg plus paracetamol 325 mg
in two (180 patients). Enteric-coated diclofenac sodium
50 mg was given every eight hours and efficacy estimates
were therefore calculated only at six and eight hours for
this drug.
Efficacy in dental pain
Table 2 shows the efficacy results for all active treatments
compared with placebo over six, eight, 12 and 24 hours in
dental pain. Using pooled data from 13 trials, the propor-
tion of patients with at least 50% pain relief with
rofecoxib 50 mg was 63% (832/1330 patients) over six
Table 2: NNT for at least 50% pain relief in dental pain
Improved with Mean percent improved with
Number of trials Drug and dose (mg) Active Placebo Relative risk (95% CI) NNT (95% CI) Placebo Active
Six hours
13 Rofecoxib 50 mg 832/1330 58/570 5.9 (4.6 to 7.5) 1.9 (1.8 to 2.1) 10 63
6 Ibuprofen 400 mg 159/303 25/298 6.3 (4.2 to 9.2) 2.3 (2.0 to 2.7) 9 53
1 Diclofenac 50 mg 32/121 8/63 2.1 (1.02 to 4.2) 7.3 (4.0 to 42) 13 26
2 Naproxen 550 mg 52/88 9/87 5.7 (3.0 to 11) 2.1 (1.6 to 2.7) 11 59
2 Oxycodone 5 mg + 
paracetamol 325 mg
30/180 5/61 2.0 (0.8 to 5.0) nc 8 17
2 Paracetamol 600 mg + 
codeine 60 mg
102/360 11/61 1.6 (0.9 to 2.7) nc 18 28
Eight hours
13 Rofecoxib 50 mg 814/1330 62/570 5.4 (4.3 to 6.9) 2.0 (1.9 to 2.1) 11 61
6 Ibuprofen 400 mg 135/303 25/298 5.3 (3.6 to 7.9) 2.8 (2.4 to 3.4) 8 44
1 Diclofenac 50 mg 32/121 11/63 1.5 (0.8 to 2.8) nc 17 26
6 Ibuprofen 400 mg 135/303 25/298 5.3 (3.6 to 7.9) 2.8 (2.4 to 3.4) 8 44
2 Naproxen 550 mg 45/88 8/87 5.6 (2.8 to 11) 2.4 (1.9 to 3.4) 10 51
2 Oxycodone 5 mg + 
paracetamol 325 mg
21/180 4/61 1.8 (0.6 to 5.0) nc 6 12
2 Paracetamol 600 mg + 
codeine 60 mg
70/360 10/61 1.2 (0.7 to 2.1) nc 16 20
Twelve hours
13 Rofecoxib 50 mg 662/1330 46/570 5.9 (4.5 to 7.8) 2.4 (2.2 to 2.6) 8 50
6 Ibuprofen 400 mg 73/303 19/298 3.8 (2.4 to 6.1) 5.6 (4.3 to 8.2) 6 24
1 Diclofenac 50 mg No data – doses repeated every 8 hours
6 Ibuprofen 400 mg 73/303 19/298 3.8 (2.4 to 6.1) 5.6 (4.3 to 8.2) 6 24
2 Naproxen 550 mg 30/88 7/87 4.2 (2.0 to 9.1) 3.9 (2.7 to 7.0) 8 34
2 Oxycodone 5 mg + 
paracetamol 325 mg
15/180 2/61 2.5 (0.6 to 11) nc 3 8
2 Paracetamol 600 mg + 
codeine 60 mg
30/360 8/61 0.6 (0.3 to 1.3) nc 13 8
Twenty-four hours
13 Rofecoxib 50 mg 595/1330 49/570 5.1 (3.9 to 6.7) 2.8 (2.5 to 3.1) 9 45
6 Ibuprofen 400 mg 43/303 21/298 2.0 (1.2 to 3.3) 14 (8.3 to 44) 7 14
1 Diclofenac 50 mg No data – doses repeated every 8 hours
6 Ibuprofen 400 mg 43/303 21/298 2.0 (1.2 to 3.3) 14 (8.3 to 44) 7 14
2 Naproxen 550 mg 24/88 8/87 3.0 (1.4 to 6.2) 5.5 (3.4 to 14) 9 27
2 Oxycodone 5 mg + 
paracetamol 325 mg
18/1804 61 1.4 (0.5 to 3.6) nc 7 10
2 Paracetamol 600 mg + 
codeine 60 mg
24/360 7/61 0.6 (0.3 to 1.2) nc 11 7
nc: not calculated because relative risk showed no statistically significant difference between active and placebo. Naproxen was given as the sodium 
saltBMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/3
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hours (Figure 1), 61% (814/1330) over eight hours, 50%
(662/1330) over 12 hours and 45% (595/1330) over 24
hours. The proportions of patients with at least 50% pain
relief with placebo at six, eight, 12 and 24 hours were 10%
(58/570; Figure 1), 11% (62/570), 8% (46/570), and 9%
(49/570). Rofecoxib 50 mg was significantly more effec-
tive than placebo at all time points. For rofecoxib 50 mg
compared with placebo, the NNT for at least 50% pain
relief was 1.9 (1.8 to 2.1) over six hours, 2.0 (1.9 to 2.1)
over eight hours, 2.4 (2.2 to 2.6) over 12 hours and 2.8
(2.5 to 3.1) over 24 hours. Rofecoxib 50 mg was statisti-
cally superior to ibuprofen 400 mg at eight (z = 3.75, p =
0.0002), 12 (z = 7.16, p = <0.00006) and 24 hours (z =
9.43, p = <0.00006).
Time to remedication in dental pain
Results for time to remedication are shown in Table 3.
Duration of analgesia was longer with rofecoxib 50 mg
than with other active comparators used in the trials. The
TTR50 was 15.5 hours with rofecoxib 50 mg, 1.6 hours
with placebo, and 7.1 hours with ibuprofen 400 mg.
Adverse effects in dental pain
Results for adverse effects are shown in Table 4. There was
no statistically significant difference in the number of
patients reporting any adverse effects with rofecoxib 50
mg (35%, 459/1330 patients) compared with placebo
(231/570, 41%), relative risk 0.9 (0.8 to 1.0).
Post-extraction alveolitis (dry socket) was reported signif-
icantly more often with rofecoxib 50 mg (179/1330,
13%) than with placebo (52/570, 9%), relative risk 1.5
(1.1 to 2.1). The NNH was 24 (14 to 80). The other most
commonly reported adverse effects were dizziness, nau-
sea, and vomiting. Significantly fewer events were
reported with rofecoxib 50 mg compared with placebo for
some adverse effects. The NNTps to prevent one event
were 43 (24 to 253) for dizziness, 18 (11 to 41) for nau-
sea, and 19 (13 to 38) for vomiting.
Ibuprofen 400 mg was not associated with significantly
increased or decreased rates of patients with any adverse
effect or particular adverse effects. One case of gastrointes-
tinal bleeding was reported with ibuprofen 400 mg,
otherwise no adverse effects were described as serious for
any intervention.
Postsurgical pain
In one trial (study 72) following major orthopaedic sur-
gery (total hip or knee replacement or femoral fracture
repair with open reduction and internal fixation), the
Table 3: Time to remedication
Pain model Drug & dose (mg) Number of trials Number of patients TRR50(hrs)
Dental Rofecoxib 50 mg 13 1330 15.5
Ibuprofen 400 mg 6 303 7.1
Diclofenac 50 mg 1 121 1.6
Ibuprofen 400 mg 6 303 7.1
Naproxen 550 mg 2 88 9.3
Oxycodone 5 mg + paracetamol 325 mg 2 180 3.1
Paracetamol 600 mg + codeine 60 mg 2 360 3.8
Placebo 13 570 1.6
Postsurgical Rofecoxib 50 mg 1 110 5.8
Naproxen 550 mg 1 55 5.9
Placebo 1 53 2.8
Naproxen was given as the sodium salt
Percent with at least 50% pain relief with rofecoxib 50 mg  over six hours Figure 1
Percent with at least 50% pain relief with rofecoxib 50 mg 
over six hours
0
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40
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Table 4: Adverse effects in dental pain
Adverse effects with 
active
Adverse effects with 
placebo
Number of trials Drug and dose Number Percent Number Percent Relative risk 
(95% CI)
NNH/NNTp 
(95% CI)
Any adverse event
13 Rofecoxib 50 mg 459/1330 35 231/570 41 0.9 (0.8 to 1.0) nc
6 Ibuprofen 400 mg 102/303 34 122/298 41 0.8 (0.7 to 1.0) nc
1 Diclofenac 50 mg* 72/121 60 31/63 41 1.2 (0.9 to 1.6) nc
6 Ibuprofen 400 mg 102/303 34 122/298 41 0.8 (0.7 to 1.0) nc
2 Naproxen 550 mg 27/88 31 25/87 29 1.1 (0.7 to 1.7) nc
2 Oxycodone 5 mg + paracetamol 325 mg 116/180 64 29/61 48 1.4 (1.02 to 1.8) 5.9 (3.2 to 39)
2 paracetamol 600 mg + codeine 60 mg 146/360 41 24/61 39 1.0 (0.7 to 1.4) nc
Post-extraction alveolitis
13 Rofecoxib 50 mg 179/1330 13 52/570 9 1.5 (1.1 to 2.1) 24 (14 to 80)
6 Ibuprofen 400 mg 23/304 8 31/298 10 0.7 (0.4 to 1.2) nc
1 Diclofenac 50 mg* 9/180 5 3/63 5 1.0 (0.3 to 3.8) nc
6 Ibuprofen 400 mg 23/304 8 31/298 10 0.7 (0.4 to 1.2) nc
2 Naproxen 550 mg 13/88 15 8/87 10 1.6 (0.7 to 3.4) nc
2 Oxycodone 5 mg + paracetamol 325 mg 20/180 11 7/61 11 0.9 (0.4 to 2.2) nc
2 Paracetamol 600 mg + codeine 60 mg 27/360 8 3/61 6 1.3 (0.5 to 3.9) nc
Dizziness
13 Rofecoxib 50 mg 30/1330 2 25/570 5 0.5 (0.3 to 0.9) 43 (24 to 253)
6 Ibuprofen 400 mg 7/304 3 13/298 5 0.6 (0.3 to 1.4) nc
1 Diclofenac 50 mg* 9/180 8 5/63 8 0.6 (0.2 to 1.8) nc
6 Ibuprofen 400 mg 7/304 3 13/298 5 0.6 (0.3 to 1.4) nc
2 Naproxen 550 mg 1/88 2 1/87 1 0.9 (0.2 to 9.3) nc
2 Oxycodone 5 mg + paracetamol 325 mg 44/180 24 6/61 10 2.5 (1.1 to 5.6) 6.9 (4.1 to 21)
2 Paracetamol 600 mg + codeine 60 mg 19/360 1 1/61 2 3.3 (0.5 to 24) nc
Drowsiness
13 Rofecoxib 50 mg 8/1330 0.6 1/570 0.6 0.9 (0.3 to 3.1) nc
6 Ibuprofen 400 mg 1/304 0.7 0/298 0.5 1.3 (0.2 to 11) nc
1 Diclofenac 50 mg* 5/180 3 0/63 0 3.5 (0.2 to 64) nc
6 Ibuprofen 400 mg 1/304 0.7 0/298 0.5 1.3 (0.2 to 11) nc
2 Naproxen 550 mg 0/88 0 0/87 0 0.9 (0.0 to 16) nc
2 Oxycodone 5 mg + paracetamol 325 mg 6/180 4 1/61 2 2.2 (0.3 to 18) nc
2 Paracetamol 600 mg + codeine 60 mg 7/360 2 1/61 2 1.2 (0.2 to 9.2) nc
Nausea
13 Rofecoxib 50 mg 112/1330 8 80/570 14 0.6 (0.5 to 0.8) 18 (11 to 41)
6 Ibuprofen 400 mg 38/304 12 51/298 17 0.7 (0.5 to 1.08) nc
1 Diclofenac 50 mg* 21/180 12 10/63 16 0.7 (0.4 to 1.5) nc
6 Ibuprofen 400 mg 38/304 12 51/298 17 0.7 (0.5 to 1.08) nc
2 Naproxen 550 mg 4/88 5 3/87 3 1.3 (0.3 to 5.7) nc
2 Oxycodone 5 mg + paracetamol 325 mg 61/180 34 10/61 17 2.0 (1.1 to 3.5) 6.0 (3.5 to 19)
2 Paracetamol 600 mg + codeine 60 mg 70/360 19 6/61 10 2.0 (0.9 to 4.4) 10 (5.5 to 92)BMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/3
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mean age of patients was 65 years, 58% were women, and
82% had moderate pain at baseline. Rofecoxib 50 mg
(110 patients) was compared with naproxen sodium 550
mg (55 patients) or placebo (53 patients). Single-dose
efficacy data were available from this five-day study; effi-
cacy data were not available for multiple doses. Multiple
dose adverse effects were collected over five days and are
described below.
Efficacy in postsurgical pain
Results are shown in Table 5. No data were available at 24
hours. The mean event rates (proportion of patients with
at least 50% pain relief) with rofecoxib 50 mg over six,
eight, and 12 hours were 39% (43/110 patients, Figure 1),
40% (44/110), and 35% (38/110). With naproxen
sodium 550 mg the mean event rates were 36% (20/55),
33% (18/55), and 25% (14/55) and with placebo were
13% (7/53) (Figure 1), 11% (6/53), and 4% (2/53).
Rofecoxib 50 mg was significantly more effective than pla-
cebo at all time points. For rofecoxib 50 mg compared
with placebo, the NNT for at least 50% pain relief was 3.9
(2.6 to 7.8) over six hours, 3.5 (2.4 to 6.9) over eight
hours, and 3.3 (2.4 to 4.9) over 12 hours. Naproxen
sodium 550 mg was significantly more effective than pla-
cebo at all time points. For naproxen sodium 550 mg
compared with placebo, the NNT for at least 50% pain
relief was 4.3 (2.6 to 13) over six hours, 4.7 (2.7 to 16)
over eight hours, and 4.6 (2.9 to 11) over 12 hours.
Time to remedication in postsurgical pain
TTR50  with rofecoxib 50 mg was similar to that of
naproxen sodium 550 mg (Table 3). It was 5.8 hours with
rofecoxib 50 mg, 5.9 hours with naproxen sodium 550
mg, and 2.8 hours with placebo.
Adverse effects in postsurgical pain
Information on adverse effects was collected over five days
for multiple doses of study treatments; single dose infor-
mation was not available. The most commonly reported
adverse effects were fever, constipation, and nausea. No
adverse effects were serious. There were too few patients to
analyse reliably particular adverse effects like dizziness or
nausea.
There was no statistically significant difference in the
reported incidence of patients with any adverse effect with
rofecoxib 50 mg (42/54 patients, 78%) compared with
placebo (41/53, 77%), relative risk 1.0 (0.8 to 1.2). With
naproxen sodium 550 mg 37/55 patients (67%) reported
adverse effects, again with no significant difference com-
pared with placebo, relative risk 0.9 (0.7 to 1.1).
Discussion
Individual patient data is the gold standard in meta-anal-
ysis and has been performed only rarely in acute pain,
with tramadol [18], and tramadol plus paracetamol [19].
This review is therefore the first individual patient data
analysis for NSAIDs and coxibs in acute pain. For
rofecoxib, individual patient information was available
from fourteen trials in postoperative pain. The trials were
of high quality and validity, scoring the maximum for
both. The same methods and outcomes were used in all
trials, thus ensuring clinical homogeneity. Since trials
were conducted over 24 hours in dental pain and 12 hours
in postsurgical pain, and because only for six hour TOT-
PAR can we be confident that there is no difference
between pain models [11], the prior decision was to ana-
lyse these two pain models separately.
Historically, single-dose analgesic trials for most treat-
ments have been conducted over 4–6 hours since this is
typically how long pain relief has lasted. Trials of coxibs,
like rofecoxib and valdecoxib [20], have been conducted
over 12–24 hours. Because of the long duration of analge-
sia at the doses given, the potential existed to use trials of
rofecoxib to calculate single dose efficacy estimates over
durations up to 24 hours in dental pain and 12 hours in
postsurgical pain. This would not have been possible
without individual patient information because methods
to convert mean summary data into dichotomous form
exist only for 4–6 hours [2-4]. Examination of efficacy
estimates over longer durations allowed examination of
the duration of analgesic effect, the caveat being that in
Vomiting
13 Rofecoxib 50 mg 51/1330 4 51/570 9 0.4 (0.3 to 0.6) 19 (13 to 38)
6 Ibuprofen 400 mg 25/304 8 36/298 12 0.7 (0.4 to 1.1) nc
1 Diclofenac 50 mg* 6/180 3 7/63 11 0.3 (0.1 to 1.0) nc
2 Naproxen 550 mg 1/88 2 1/87 2 0.9 (0.1 to 9.3) nc
2 Oxycodone 5 mg + paracetamol 325 mg 35/180 19 3/61 6 3.4 (1.2 to 9.8) 7.2 (4.6 to 18)
2 Paracetamol 600 mg + codeine 60 mg 58/360 16 4/61 7 2.46 (0.9 to 6.5) 10 (5.9 to 44)
*NB: Diclofenac was taken every eight hours during the study. Naproxen was given as the sodium salt Bold type: NNTp to prevent one event 
(significantly fewer events occurred with rofecoxib 50 mg compared with placebo
Table 4: Adverse effects in dental pain (Continued)BMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/3
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some studies there was only one additional observation
beyond 12 hours.
In dental pain the six-hour NNTs for rofecoxib 50 mg and
ibuprofen 400 mg were similar at about two. This means
that for every two patients treated one would obtain at
least 50% pain relief with active treatment who would not
have done with placebo. For rofecoxib 50 mg the NNTs
were similar (all below 3) at six, eight, 12 and 24 hours,
whereas for ibuprofen 400 mg the NNTs increased (drug
less effective) with time (Figure 2). This comparison of
rofecoxib 50 mg with ibuprofen 400 mg at longer times is
the only one we have with adequate numbers of patients.
External, or indirect, comparisons are only available over
six hours. Table 6 shows a comparison for coxibs, NSAIDs,
and simple analgesics over six hours after third molar
surgery [20,21]. Oral rofecoxib 50 mg and valdecoxib 20
mg and 40 mg all have mean NNT values below 2, and
have overlapping confidence intervals. Standard doses of
diclofenac and ibuprofen have similar, if slightly higher,
NNTs, while standard doses of paracetamol and aspirin
have considerably higher (worse) NNTs.
In this analysis, time for 50% of patients to have remedi-
cated was calculated for each drug and for placebo from
individual patients. The results showed that in dental pain
the duration of analgesia was longer with a single dose of
rofecoxib 50 mg than for other comparator drugs (at the
doses used in the trials). In the postsurgical trial TTR50 was
shorter at 5.8 hours. The difference in TTR50 values for
dental compared with postsurgical pain may be due to the
different pain context (more major orthopaedic than den-
tal surgery), the more elderly population in the postsurgi-
cal study (mean age 65 years versus 21 years in the dental
trials), and that results were simply not robust in the post-
surgical study because they were based on too little infor-
mation. Oral valdecoxib 20 mg or 40 mg has comparable
duration of analgesia to rofecoxib 50 mg in dental studies
[20], though in many fewer patients.
Overall, efficacy results for rofecoxib 50 mg from this indi-
vidual patient meta-analysis were similar to those derived
using published mean summary data [5]. There were
minor differences. For instance, the NNT for at least 50%
pain relief over 4–6 hours from five published trials with
675 patients in the comparison was 2.3 (2.0 to 2.6) in
dental plus postsurgical pain. Here, in all 14 trials with
2060 patients it was 2.0 (1.9 to 2.1) in dental plus post-
surgical pain. Again, the previous estimate for duration of
analgesia using time to remedication calculated from
weighted mean values was 13.6 hours, and here it was
15.5 hours measured from individual patients (though in
dental pain only).
Adverse effects are also important, though in single dose
trials they are both uncommon and inadequately reported
Table 5: NNT for at least 50% pain relief in postsurgical pain
Improved with Mean percent improved with
Time (hours) Drug and dose (mg) Active Placebo Relative risk (95% CI) NNT (95% CI) Placebo Active
6 Rofecoxib 50 mg 43/110 7/53 3.0 (1.4 to 6.1) 3.9 (2.6 to 7.8) 13 39
Naproxen 550 mg 20/55 7/53 2.8 (1.3 to 6.0) 4.3 (2.6 to 13) 13 36
8 Rofecoxib 50 mg 44/110 6/53 3.5 (1.6 to 7.8) 3.5 (2.4 to 6.9) 11 40
Naproxen 550 mg 18/55 6/53 2.9 (1.2 to 6.7) 4.7 (2.7 to 16) 11 33
12 Rofecoxib 50 mg 38/110 2/53 9.2 (2.3 to 37) 3.3 (2.4 to 4.9) 4 35
Naproxen 550 mg 14/55 2/53 6.8 (1.6 to 28) 4.6 (2.9 to 11) 4 25
Naproxen was given as the sodium salt
Comparison of NNTs of rofecoxib 50 mg and ibuprofen 400  mg over different times Figure 2
Comparison of NNTs of rofecoxib 50 mg and ibuprofen 400 
mg over different times
6 8 12 24
1
3
5
7
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11
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NNT for at least 50% pain relief
Time of observation (hours)
Rofecoxib 50 mg Ibuprofen 400 mgBMC Anesthesiology 2004, 4 http://www.biomedcentral.com/1471-2253/4/3
Page 9 of 10
(page number not for citation purposes)
[22]. Information from many patients is required to deter-
mine NNH reliably even for relatively common, minor,
events like dizziness or nausea [23]. Adverse effects were
uncommon with single doses of rofecoxib 50 mg, and
rates of particular adverse effects were low. There is no
obvious reason for post-extraction alveolitis with
rofecoxib; the incidence with rofecoxib 50 mg (13%) was
similar to that with comparator NSAIDs (5–15%, Table
4). Central nervous system and gastrointestinal effects
would be expected with the opioid combination compa-
rators, though results were based on few patients and
NNHs were not robust.
Surveys have shown that acute pain is often not managed
well [24]. Potential exists for better pain management
since drugs with fast onset and long-lasting analgesic
action are available. Information on remedication in trials
may help demonstrate duration of analgesia with differ-
ent treatments, since patients are meant to remedicate
only when they have inadequate pain relief. Longer dura-
tion analgesics may be of importance, not only as part of
a multimodal approach to analgesia in the perioperative
period [25]. A recent survey of French general practition-
ers found acute pain at home after hospital discharge to be
a major problem [26].
Conclusions
Single dose rofecoxib 50 mg in dental pain had compara-
ble analgesia to ibuprofen 400 mg over six hours, but was
superior at eight and 12 hours. Adverse effects were
uncommon. Results for postsurgical pain were not robust
because of limited patient numbers.
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